Table 1.
Relation between AIDS clinical courses and nef dsRNA or siRNA/miRNA in suppression of nef gene expression
| Nef inhibitor | Nef expressed by: | Target region | Clinical courses | ||
| Nef-EGFP | HIV-1 IIIB | PFV/nef | |||
| dsRNA* | Human | ||||
| SF2 | ++ † | ++ | ND‡ | Full-length (including miR-N367) | ND |
| 1-3-3 | ++ | - | ND | U3 deleted | Rapid progressor, Died within 3 years |
| 4-2-1 | ND | + | ND | U3 region (including miR-N367) | Rapid progressor, Died within 3 years |
| 15-2-2 | ++ | +++ | ND | U3 region (including miR-N367) | Non progressor with low plasma viremia |
| 16-1-1 | ND | + | ND | U3 deleted | Non progressor with low plasma viremia |
| jw95-1 | ND | + | ND | U3 region (including miR-N367) | Non progressor with undetectable viremia |
| siRNA | 15-2-2 model mouse | ||||
| dsnef | + | + | + | Full-length | ND |
| sinef007 | + | ND | ND | Upstream of U3 region | ND |
| sinef084 | + | ND | ND | Upstream of U3 region | ND |
| sinef176 | +++ | +++ | ++ | Upstream of U3 region§ | ND |
| sinef190 | +++ | +++ | +++ | Upstream of U3 region | ND |
| sinef299 | + | ND | ND | U3 region (aa 83–135) | ND |
| sinef367/miR-N367 | ++ | +++ | ++ | U3 region | No weight loss |
| sinef468 | + | ND | ND | U3 region | ND |
| sinef580 | + | ND | ND | U3 region | ND |
*dsRNA to LTNPs' nef has been described (Yamamoto et al., 2002).
† -, negative; +, 0 to 50 % inhibition; ++, 50 to 75% inhibition; +++, 75 to 100 % inhibition.
‡ ND, not done.